PharmAla BiotechCSE: MDMA | OTCQB: MDXXF

Actual: Dec 13, 2022

Pre-IND meeting completed with FDA. ALA-002 dossier submitted November 2022, FDA meeting held December 2022. FDA classifies ALA-002 as a Novel Chemical Entity (NCE), separate active moiety from racemic MDMA.

Why it matters: NCE classification is a major regulatory win — ALA-002 gets its own data exclusivity upon approval, is not subject to the Lykos/racemic MDMA regulatory baggage, and the safety concerns cited in the FDA AdCom rejection (cardiovascular risk, hyperthermia, functional unblinding) are precisely what the non-racemic formulation is designed to address.

Actual: Jul 20, 2023

UK MHRA provides guidance that no further preclinical data is needed before clinical trials of ALA-002. Clinical development agreement signed with University of Sydney; Dr. Adam Guastella named lead investigator; Phase 2 protocol completed.

Why it matters: MHRA green light on preclinical package reduces development cost and timeline. University of Sydney partnership provides access to world-leading ASD clinical research expertise (Guastella lab) and Australian TGA regulatory pathway.

Actual: Aug 9, 2024

US Patent 12,053,452 formally issued for ALA-002 composition of matter — non-racemic MDMA formulation (70-80% R-MDMA / 20-30% S-MDMA). Patent allowance first granted March 2024.

Why it matters: Composition of matter patent is the strongest form of IP protection. Combined with FDA NCE classification, provides dual regulatory and IP moats. Differentiates from pure R-MDMA approaches (Definium DT402, AtaiBeckley EMP-01) and racemic MDMA (Lykos).

Actual: Dec 15, 2025

UK-based CDMO contracted for manufacture of ALA-002 drug substance. CDMO name undisclosed due to controlled substance regulatory sensitivity. Capsule encapsulation on production schedule for 2026 Phase 2 trial supply.

Why it matters: Drug substance manufacturing is the critical gating step before Phase 2 can begin. CDMO engagement signals imminent clinical trial initiation in 2026.

Actual: Mar 20, 2024

USPTO patent allowance granted for APA-001 (formerly P-1) composition of matter. Novel MDXX molecule discovered via in-silico computational modelling.

Why it matters: First drug candidate from Phenesafe AI platform. Composition of matter patent protects a structurally novel compound — not a reformulation of existing MDMA. Validates computational drug discovery approach for psychedelic-adjacent molecules.

Actual: May 15, 2025

Phenesafe AI drug discovery platform launched — world's first computational value chain for novel phenethylamine/MDXX-class molecules. Combines QSAR model (University of Windsor) with AI chemical pathway modelling.

Why it matters: Platform approach enables systematic discovery of novel MDXX molecules beyond APA-001. Could accelerate pipeline expansion if initial candidates show clinical promise.